Uniqure (NASDAQ:QURE) PT Set at $73.00 by HC Wainwright

HC Wainwright set a $73.00 price target on Uniqure (NASDAQ:QURE) in a report released on Monday, Stock Target Advisor reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

Several other equities research analysts have also recently weighed in on QURE. Zacks Investment Research raised SCHNEIDER ELEC /ADR from a hold rating to a buy rating and set a $20.00 price objective on the stock in a research note on Friday, July 5th. BidaskClub cut Xilinx from a buy rating to a hold rating in a research note on Saturday, June 15th. SunTrust Banks upped their target price on Everbridge to $87.00 and gave the company a buy rating in a research note on Tuesday, May 7th. Janney Montgomery Scott reissued a buy rating on shares of Uniqure in a research note on Tuesday, June 11th. Finally, Wells Fargo & Co reissued a hold rating on shares of Broadcom in a research note on Friday, March 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus price target of $77.00.

Shares of NASDAQ QURE opened at $68.65 on Monday. The stock’s 50 day moving average is $71.72. The company has a quick ratio of 9.51, a current ratio of 9.51 and a debt-to-equity ratio of 0.38. Uniqure has a 1-year low of $21.98 and a 1-year high of $82.49. The company has a market capitalization of $2.66 billion, a PE ratio of -29.34 and a beta of 1.05.

Uniqure (NASDAQ:QURE) last issued its quarterly earnings data on Monday, April 29th. The biotechnology company reported ($0.74) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.71) by ($0.03). Uniqure had a negative return on equity of 48.90% and a negative net margin of 1,032.06%. The company had revenue of $1.14 million for the quarter, compared to the consensus estimate of $2.00 million. As a group, equities analysts predict that Uniqure will post -3.01 EPS for the current year.

In other Uniqure news, CEO Matthew C. Kapusta sold 8,000 shares of the company’s stock in a transaction on Wednesday, June 19th. The stock was sold at an average price of $77.45, for a total transaction of $619,600.00. Following the completion of the sale, the chief executive officer now owns 409,407 shares in the company, valued at $31,708,572.15. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Christian Klemt sold 1,546 shares of the company’s stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $57.18, for a total value of $88,400.28. Following the sale, the insider now owns 54,539 shares of the company’s stock, valued at approximately $3,118,540.02. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 23,546 shares of company stock valued at $1,556,820. 2.91% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of the business. Advisor Group Inc. grew its position in Uniqure by 5.3% in the fourth quarter. Advisor Group Inc. now owns 9,966 shares of the biotechnology company’s stock valued at $288,000 after acquiring an additional 502 shares during the last quarter. Northern Trust Corp grew its position in Uniqure by 2.5% in the fourth quarter. Northern Trust Corp now owns 33,086 shares of the biotechnology company’s stock valued at $954,000 after acquiring an additional 797 shares during the last quarter. Geode Capital Management LLC grew its position in Uniqure by 75.9% in the fourth quarter. Geode Capital Management LLC now owns 35,445 shares of the biotechnology company’s stock valued at $1,021,000 after acquiring an additional 15,295 shares during the last quarter. Lord Abbett & CO. LLC grew its position in Uniqure by 2.5% in the fourth quarter. Lord Abbett & CO. LLC now owns 151,271 shares of the biotechnology company’s stock valued at $4,359,000 after acquiring an additional 3,682 shares during the last quarter. Finally, Sphera Funds Management LTD. grew its position in Uniqure by 30.9% in the fourth quarter. Sphera Funds Management LTD. now owns 232,849 shares of the biotechnology company’s stock valued at $6,711,000 after acquiring an additional 55,000 shares during the last quarter. Institutional investors own 60.10% of the company’s stock.

Uniqure Company Profile

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.

Read More: Why is insider trading harmful?

Analyst Recommendations for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.